Windtree Therapeutics initiates SEISMiC C study of istaroxime

Windtree Therapeutics (WINT) announced the initiation of enrollment in the SEISMiC C trial in SCAI Stage C cardiogenic shock. This study follows the positive results in both SEISMiC A and B in SCAI Stage B cardiogenic shock trials. In these trials, istaroxime improved systolic blood pressure, cardiac function and renal function without an increased risk for cardiac arrhythmias, a profile that differentiates istaroxime from currently used medications to treat shock. SCAI Stage C cardiogenic shock is a more severely ill population than was previously studied with istaroxime. SCAI Stage C patients have progressed in their cardiogenic shock and heart failure to the point of tissue and vital organ hypoperfusion and typically require inotropic or vasopressor drugs for support. The Company intends to include SCAI Stage C patients as part of the Phase 3 patient population for cardiogenic shock.